| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.21 | 7e-05 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 9e-05 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.18 | 0.0001 |